Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,320Revenue $M85.6Net Margin (%)-18.6Z-Score12.4
Enterprise Value $M3,273EPS $-1.9Operating Margin %-13.5F-Score7
P/E(ttm))0Cash Flow Per Share $-2.0Pre-tax Margin (%)-18.6Higher ROA y-yY
Price/Book21.410-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsY
Price/Sales18.95-y EBITDA Growth Rate %-62.0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-14.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-36.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M36.1ROI % (ttm)-53.4Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXJoel Greenblatt 2014-09-30 Reduce$83.31 - $108.26
($97.65)
$ 92.09-6%Reduce -26.78%6,946
PCRXMariko Gordon 2014-09-30 Reduce-1.21%$83.31 - $108.26
($97.65)
$ 92.09-6%Reduce -28.09%814,470
PCRXRon Baron 2014-09-30 Reduce-0.03%$83.31 - $108.26
($97.65)
$ 92.09-6%Reduce -59.75%62,139
PCRXRon Baron 2014-06-30 Add0.05%$63.61 - $91.01
($75.89)
$ 92.0921%Add 802.88%154,393
PCRXJoel Greenblatt 2014-06-30 Buy 0.01%$63.61 - $91.01
($75.89)
$ 92.0921%New holding, 9486 sh.9,486
PCRXMariko Gordon 2014-06-30 Reduce-0.66%$63.61 - $91.01
($75.89)
$ 92.0921%Reduce -17.39%1,132,552
PCRXMariko Gordon 2014-03-31 Add0.19%$55.83 - $80.43
($67.63)
$ 92.0936%Add 5.13%1,371,042
PCRXRon Baron 2014-03-31 Add$55.83 - $80.43
($67.63)
$ 92.0936%Add 163.28%17,100
PCRXMariko Gordon 2013-12-31 Add2.08%$47.74 - $56.97
($52.53)
$ 92.0975%Add 203.52%1,304,190
PCRXRon Baron 2013-12-31 Buy $47.74 - $56.97
($52.53)
$ 92.0975%New holding, 6495 sh.6,495
PCRXMariko Gordon 2013-09-30 Add0.93%$30.01 - $47.47
($36.37)
$ 92.09153%Add 3812.66%429,688
PCRXMariko Gordon 2013-06-30 Buy 0.02%$25.84 - $30.26
($28.93)
$ 92.09218%New holding, 10982 sh.10,982
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PCRX Joel Greenblatt 2014-09-306,9460.020.01-26.78%
PCRX Mariko Gordon 2014-09-30814,4702.263.5-28.09%
PCRX Ron Baron 2014-09-3062,1390.170.03-59.75%
Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WINGER DENNIS LDirector 2014-12-05Buy2,645$94.54-2.59view
Markvicka TauniaSVP, Chief Commercial Officer 2014-11-07Buy230$86.626.31view
Scibetta James SSVP, CFO 2014-11-07Sell15,000$87.185.63view
Kronenfeld Mark A.Director 2014-11-03Buy850$90.481.78view
STACK DAVID MPresident, CEO and Chairman 2014-10-15Sell15,000$99.49-7.44view
HASTINGS PAUL JDirector 2014-10-10Sell2,500$94.87-2.93view
LONGENECKER JOHN P PHDDirector 2014-09-29Sell1,000$96.4-4.47view
Wicki AndreasDirector 2014-08-29Sell21,494$108.11-14.82view
Wicki AndreasDirector 2014-08-27Sell55,813$108.08-14.79view
Wicki AndreasDirector 2014-08-11Sell150,000$101.25-9.05view

Press Releases about PCRX :

    Quarterly/Annual Reports about PCRX:

    News about PCRX:

    Articles On GuruFocus.com
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Pharmace Nov 28 2014 
    Mariko Gordon's First Quarter Top Five May 15 2014 
    Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
    comment on PCRX Mar 15 2013 
    Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
    Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Dec 24 2014
    Aratana Therapeutics Initiates Pivotal Study for AT-003 Dec 16 2014
    Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label Dec 12 2014
    Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label Dec 12 2014
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira... Nov 28 2014
    Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
    Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
    UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira... Nov 24 2014
    EQUITY ALERT: Rosen Law Firm Reminds Pacira Pharmaceuticals, Inc. Investors of Important December 2,... Nov 21 2014
    SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 19 2014
    Pacira Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Nov 18 2014
    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira... Nov 17 2014
    DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Pacira Pharmaceuticals, Inc. Of... Nov 17 2014
    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Pacira... Nov 17 2014
    Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference Nov 11 2014
    Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain... Nov 06 2014
    Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain... Nov 06 2014
    PACIRA PHARMACEUTICALS, INC. Financials Nov 06 2014
    10-Q for Pacira Pharmaceuticals, Inc. Nov 01 2014
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Pacira... Oct 31 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK